Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company developing therapeutics for disease indications with markets. The Company’s wholly-owned subsidiary, Transition Therapeutics Ireland Limited is developing CNS drug candidate ELND005 for the treatment of Alzheimer’s disease and Down syndrome. The Company’s technologies in development include ELND005 for the treatment of Alzheimer’s disease, bipolar disorder and Down syndrome, and TT401/402 for the treatment of diabetes. The Company is engaged in developing disease-modifying small molecule therapeutics that act by preventing the formation of and breaking down amyloid beta peptide aggregates. TT-401 provides glycemic control and other effects, including weight loss.